By Editor , 1 October 2026
Hoymiles Supplies 300 Microinverters for Freiburg Solar Upcycling Event

Freiburg, Germany – October 01, 2026 -- Hoymiles supplied 300 microinverters to convert 600 used solar panels into plug-in photovoltaic systems during an upcycling event in Freiburg, Germany, marking the company's third consecutive year supporting the initiative.

By Editor , 1 October 2026

Birkirkara, Malta – October 01, 2026 -- Gentoo Media Inc. has locked in commitments worth EUR 100 million to refinance its EUR 91.5 million senior secured bonds maturing 18 December 2026, combining a new EUR 50 million term loan with a fully underwritten EUR 50 million share issue.

By Editor , 1 October 2026

STOCKHOLM – October 01, 2026 -- Ericsson (NASDAQ: ERIC) will publish its third-quarter 2026 financial report at approximately 7:00 AM CEST on October 15, 2026, the Stockholm-based telecom equipment maker confirmed.

Ericsson sets October 15 release date with full PDF financial tables

The company will issue a press release with the complete financial report attached, including detailed tables in PDF format. The report will be posted on Ericsson's investor relations website immediately following the press release.

By Editor , 1 October 2026

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

By Editor , 1 October 2026

St. Helena, Calif. – October 01, 2026 -- Tres Agaves Tequila launched in the UK and Ireland on October 1, marking the family-owned Mexican producer's first entry into European on-premise and independent retail channels. The rollout extends to Germany, Switzerland, the Nordics and Spain in the following months, with a formal European trade introduction scheduled at Bar Convent Berlin in mid-October.

By Editor , 1 October 2026
ICEYE, Nokia Partner on Sovereign Satellite Comms for 2028 Launch

Helsinki – October 01, 2026 -- ICEYE and Nokia have agreed to jointly develop secure, sovereign low Earth orbit (LEO) satellite communications systems for governments and defense customers, with the first satellites expected to launch in 2028.

By Editor , 1 October 2026
Hankook Tires WRC Finale as Toyota Clinches Sixth Straight Title

Alghero – October 01, 2026 -- Hankook Tire & Technology, the exclusive tire supplier to the FIA World Rally Championship, will equip all competitors at Rally Italia Sardegna, the season-closing round running October 1-4 around Alghero on Italy's Sardinia island.

By Editor , 1 October 2026
Aviation Giants Form Coalition to Shape EU Biometric Travel Rules

Courbevoie – October 01, 2026 -- ACI EUROPE, Amadeus, IATA, IDEMIA Public Security and SITA have formed the Responsible Biometrics Travel Industry Coalition, pressing EU policymakers to prevent the bloc's Digital Omnibus legislation from restricting voluntary biometric use in air travel.

The five organizations argue the current legislative proposal, designed to simplify Europe's digital rulebook and strengthen competitiveness, could unintentionally curb passengers' ability to opt into biometric verification at airports.

By Editor , 1 October 2026
Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.

By Editor , 30 September 2026
Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.